TerminatedNCT05803551
A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients
This study assesses depression symptoms.
Medication studyAges 18–99United States
Understand this study
What is this study about?
This study assesses depression symptoms.
Who could participate?
Listed age limits: 18 years to 99 years.
- Listed locations
- JacksonvilleSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 7, 2025
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 1
- Sponsor
- Mayo Clinic
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 99 Years
- Official registry ID
- NCT05803551
- Official title
Show the full official title
A Phase II Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effects of Ketamine Infusions in Clinically Depressed ICU Patients
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Jacksonville
Interested in joining this study?
Questions about this study
What is this study about?
This study assesses depression symptoms.
Who is behind this study?
The study sponsor is Mayo Clinic, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Ketamine Hydrochloride and Placebo.
Who can participate?
Listed age limits: 18 years to 99 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolarity type I.